PTC Therapeutics, Inc. (PTCT) Earnings
PTC Therapeutics, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $0.28. PTCT has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise -115.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.45 | $-0.03 | +93.3% | $273M | +25.4% |
| Feb 19, 2026 | $-0.21 | $-1.67 | -695.2% | $165M | -33.3% |
| Nov 4, 2025 | $-1.19 | $0.20 | +116.8% | $211M | -25.0% |
| Aug 7, 2025 | $-1.07 | $-0.83 | +22.4% | $179M | -6.6% |
| Feb 27, 2025 | $-1.12 | $-0.24 | +78.6% | $213M | -14.4% |
| Nov 7, 2024 | $-1.54 | $-1.39 | +9.7% | $197M | +3.3% |
| Aug 8, 2024 | $-1.00 | $-1.16 | -16.0% | $187M | +0.7% |
| Apr 25, 2024 | $-1.21 | $-1.20 | +0.8% | $210M | +23.3% |
| Feb 29, 2024 | $0.29 | $-0.24 | -182.8% | $307M | -4.4% |
| Oct 26, 2023 | $-0.85 | $-1.76 | -107.1% | $197M | -6.5% |
| Aug 3, 2023 | $-1.58 | $-2.66 | -68.4% | $214M | +3.3% |
| Apr 27, 2023 | $-1.64 | $-1.88 | -14.6% | $220M | +7.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• CEO Dr. Matthew Klein noted a record quarter of product revenue led by Suffiance launch and mature products. First quarter total revenue $273 million, product revenue $226 million. Raised 2026 full-year product revenue guidance to $750 - $850 million, total revenue to $1.08 - $1.18 billion. • Update on Suffiance Global launch: First quarter global revenue $125 million, 36% QoQ growth, U.S. revenue $112 million. As of March 31st, 1,244 commercial patients globally, over 1,500 patient start forms in U.S. with 140 per month cadence. Launched in Japan ahead of schedule, on plan to have commercial sales in up to 30 countries by year end. Over 90% of U.S. centers of excellence have prescribed Suffiance. • Vodafone Huntington's disease program: Positive top line results from 24 month interim analysis of pivot HD long term extension study, showing dose dependent slowing of disease progression. Increased confidence in InvestHD study. • Vaticanone: Had Type C meeting with FDA in April to discuss design of new trial for NDA resubmission, moving forward with open-label study with matched natural history control group from FACOMS disease registry. • Pipeline updates: Expect to initiate Phase I study of PTC612 in second quarter. Good progress on other pipeline programs including MSH3 oral splicing program for HD and DM1, and programs from inflammation and theroptosis platform. • Commercial update from Eric Powles: Suffiance global launch accelerating, U.S. revenue strong, international revenue ramping with commercial patients in up to 30 countries by year end. DMD franchise delivered solid first quarter performance despite headwinds.
Guidance
• Raised 2026 full-year product revenue guidance to $750 to $850 million, with expected total revenue of $1.08 to $1.18 billion. • Suffiance global launch momentum expected to continue with growth accelerating internationally. • Confidence in the success of Vodafone's InvestHD study and the potential of Vaticanone's new trial design. • Expect to initiate Phase I study of PTC612 in second quarter.
Segment performance
First quarter total revenue was $273 million, including $226 million of product revenue. Product revenue in the first quarter includes $125 million from Suffiance global launch, $81 million from DMD franchise (Translarna driven by a large government purchase order in Brazil, Implaza generated $22 million), $59 million from Translarna, $22 million from MFLASA, and royalty revenue of $47 million from ERISD. Suffiance global revenue in first quarter was $125 million, representing 36% quarter-over-quarter growth, with U.S. revenue of $112 million. As of March 31st, there were 1,244 commercial patients globally on Suffiance, and in the U.S., over 1,500 patient start forms with a consistent cadence of prescription starts averaging 140 per month over the past few months. Suffiance contributed 36% of the first quarter product revenue.
Analyst Q&A
Q: Kristen Kliska with Kent Office Gerald asked about patterns in real world with Suffiance, compliance, long-term utilization and factors driving patients staying on therapy.
A: Matt Klein said it's a combination of diet liberalization, other benefits like improved anxiety, cognition, real-world evidence papers being compiled. Eric Powles added low double digit discontinuations, mostly not due to efficacy or safety, some patient choice.
Q: Tazin Ahmed with Bank of America asked about start forms trend and discontinuation.
A: Matt Klein said 140 per month run rate likely to continue, Eric Powles added low double digit discontinuations, mostly from hard to treat patients with good benefit.
Q: Ben Burnett with Wells Fargo asked about average weight, price and international impact.
A: Matt Klein said average weight in 45 - 50 range, international dynamics play in, continue to watch.
Q: Ellie Murphy with Barclays asked about XUS opportunity, pricing and cadence of XUS sales.
A: Eric Powles said U.S. still main driver this year, international revenue to ramp, Japan started early, pricing and reimbursement finalized in Japan, HTA assessments in Europe.
Q: Brian Cheng with JPMorgan Chase asked about remaining 10% of centers not prescribing Suffiance.
A: Matt Klein said very bullish on opportunity, Eric Powles said remaining centers are late adopters, smaller centers, working on them.
Q: Judith with Morgan Stanley asked about separating one-time TransLarna order from guidance and vaticanone study.
A: Matt Klein said increased guidance based on quarter performance, vaticanone study using natural history control group to support NDA resubmission.
Q: Jeff Meacham with Citigroup asked about Japan launch pattern, social media success in other geographies and sensitivity of MFARS in vaticanone's open-label study.
A: Eric Powles said Japan launch off to great start, social media global, FDA has guidance on natural history control group.
Q: Brian Abrahams with RBC Capital Markets asked about Suffiance payer dynamics and prior authorization delays.
A: Eric Powles said payer dynamics favorable, very few step edits, prior authorizations easy to get through, time to dispense improving.
Q: Yifan Su with Jeffrey asked about PKU patient split and 2 billion peak sales guidance split.
A: Matt Klein said don't collect specific split, contributions consistent across patient segments, confident in multi-billion peak.
Q: Jacob on for Joseph Combe at TD Cowen asked about time for patients to get on Suffiance by geography.
A: Eric Powles said U.S. rapid, global different based on country, named patient programs can take weeks or months.
Q: Luke Herman with Bayer asked about U.S. reimbursement for Suffiance and vaticanone's open-label study details.
A: Eric Powles said very few limitations, Matt Klein said vaticanone's open-label study using matched natural history cohort, provisions for SkyClaris use.
Q: Joseph Swartz with Learing Partners asked about long-term PKU competitive setup and Suffiance defensibility.
A: Matt Klein said Suffiance has first mover advantage, complementary to other therapies, not worried about significant threat.
Q: Paul Choi with Goldman Sachs asked about vaticanone's natural history in FA and cash balance.
A: Matt Klein said natural history in FA well-characterized, cash position strong, looking for right business development opportunities.